**Company Announcement**
No. 24/2012

# Zealand Pharma A/S

# Financial Calendar for 2013

*Copenhagen, 12 December 2012* – Zealand Pharma (NASDAQ OMX Copenhagen: ZEAL) announces the following dates for the company's planned financial reporting in 2013:

| | |
|---|---|
| 14 March | Annual Report 2012 |
| 15 May | Interim report, 3 months 2013 |
| 29 August | Interim report, 1H 2013 |
| 15 November | Interim report, 9 months 2013 |

The Annual General Meeting will be held on Tuesday 30 April 2013, at the company's address; Smedeland 36, 2600 Glostrup – Copenhagen, Denmark.

The Financial Calendar for 2013 is also available in the Investor section of the company's website; www.zealandpharma.com.

# # #

**For further information, please contact:**

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: hlh@zealandpharma.com

**About Zealand Pharma**

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia® [1]), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. In November 2012, lixisenatide was given a CHMP positive opinion in Europe and a regulatory filing in the United States is expected in December 2012.

Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Abbott in acute kidney injury and Helsinn Healthcare in chemotherapy induced diarrhea. Zealand Pharma focuses its activities in disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com

1. Lyxumia is the proprietary name submitted to the EMA for lixisenatide. The proprietary name for lixisenatide in the United States is under consideration. Lixisenatide is not currently approved or licensed anywhere in the world.